To compare the efficacy and tolerability of (90)Y-DOTATOC vs (177)Lu-DOTATATE vs (90)Y-DOTATOC+(177)Lu-DOTATATE in advanced bronchopulmonary carcinoid.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Yttrium-90-DOTATOC (Primary)
- Indications Carcinoid tumour; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2016 New trial record